Two-thirds of Lilly sales from GLP-1s
Approximately two-thirds of Eli Lilly's total sales come from GLP-1-related products, making it essentially a pure-play index fund on the technology.
Snapshot · The Prof G Pod with Scott Galloway
Why People Are Losing Faith in Healthcare
Explore episode
Jun 4, 2026
Where this was said
The GLP-1 Revolution: Why This Technology Is Different
At 9:31 · chapter starts 7:50
Most chronic disease drugs, Ricks explains, work for some people and not others — and patients typically feel worse taking them. GLP-1s break this pattern on both counts: nearly universal efficacy and a subjective experience patients actually welcome. That's unusual. Add the fact that obesity connects causally to more than 200 chronic diseases — from diabetes and cardiovascular disease to inflammation and cancer — and you have what Ricks calls a 'nodal' health condition. Fix obesity at scale and you potentially pull down a cascade of downstream costs and suffering. Galloway layers in the macro: US healthcare costs $13,500 per person versus Japan's $5,500, and the countries' obesity rates differ by roughly 36 percentage points. His thesis: you cannot address the US fiscal deficit without addressing healthcare, and you cannot address healthcare without addressing obesity. Ricks largely agrees.
US healthcare: $13,500/person vs Japan $5,500
The US spends $13,500 per person on healthcare versus Japan's $5,500, with the US having a 40% obesity rate compared to Japan's 4%.
America's Obesity Bill: $1.4 Trillion a Year
About a third of all US healthcare spending is obesity-related — roughly $1.4 trillion annually. That's comparable to the entire US Defense Department budget, and it's almost entirely driven by downstream chronic diseases like diabetes, cardiovascular disease, and joint failure.
Obesity costs $1.4 trillion/year
About a third of all US healthcare spending — roughly $1.4 trillion per year — is obesity-related, comparable in scale to the entire Defense Department budget.
GLP-1s: More Than Weight Loss — A Nodal Health Revolution
GLP-1 drugs don't just help people lose weight — they reduce inflammation, cardiovascular disease risk, and are linked to lower cancer rates. Obesity is a nodal condition upstream of over 200 chronic diseases, making these drugs uniquely high-leverage for public health.
Similar snapshots
80% of time above the fold
Focus 80% of your landing page design effort on the hero section — the first thing visitors see when they open the website.
Hero section carries full message
The hero section must convey the product's complete value proposition on its own, so visitors instantly understand what it is.
First couple of seconds matter most
Visitors decide whether to stay or leave within just a few seconds, so immediate clarity is essential on any landing page.
Pain-point headline drives conversion
Highlighting time savings, money savings, or a painful problem solved in the headline and subheading is the core conversion lever.
Big CTA essential above the fold
A prominent call-to-action must accompany the headline and subheading in the hero section to capture visitor intent immediately.
$25K/month revenue
Avnish's solopreneur business reached $25,000 per month in revenue using a community-driven, zero-ad-spend marketing strategy.
15 months to $25K/month
Avnish scaled his business from zero to $25K/month in just 15 months using a single core marketing strategy.
Zero marketing spend
Avnish acquired thousands of users without spending any money on marketing, relying entirely on Reddit and Facebook groups.
Single thousands to tens of thousands of users
One specific Reddit or Facebook post was responsible for taking Avnish's user base from single thousands to tens of thousands.
